Lysine demethylase 4C (KDM4C) is a chromatin-modifying protein frequently overexpressed across multiple solid and hematological cancers (including breast, lung, colon, prostate, esophageal cancers and lymphomas) and has been linked to chromatin instability and enhanced cell proliferation and stem cell-like behavior.
Ovarian cancer is a highly lethal gynecological malignancy with limited therapeutic options for recurrent and drug-resistant disease. Sirtuin 2 (SIRT2) promotes tumor cell proliferation, migration and invasion by regulating multiple oncogenic signaling pathways. Although SIRT2 has emerged as a promising therapeutic target, conventional inhibitors often result in incomplete and transient suppression of its activity.
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a post-translational modification that modulates cullin-RING ligases and has arisen as a crucial regulator of protein turnover in cancer.
Researchers from Leiden University Medical Center previously demonstrated that the junction adhesion molecule-independent mutant (jin-3) reovirus, which is a double-stranded RNA virus not associated with severe human disease, presents extended tumor tropism compared to wild-type reoviruses.
Recent evidence has suggested threonine tyrosine kinase (TTK) as a crucial element of the mitotic checkpoint for the correct functioning of spindle assembly checkpoint (SAC), making it a potential therapeutic target in cancer.
Researchers from Lanzhou University and Southern Medical University (China) have presented the discovery of a structurally distinct pyrimidine-based chemotype for the inhibition of KRAS G12C.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common pediatric cancer. Although pediatric ALL is cured in over 90% of cases, children with high-risk BCP-ALL present increased chance of treatment failure and relapse.
Acerand Therapeutics (Hong Kong) Ltd. has divulged new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.
Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.
RSS
